Geneva, Switzerland – June 6,2024 – A collaborative study involving leading hospitals in Switzerland and Spain has identified promising blood biomarkers for the management of pediatric mild traumatic brain injury (mTBI). The study, led by Anne-Cécile Chiollaz and published today in Neurotrauma Reports, highlights the potential of S100b, Glial Fibrillary Acidic Protein (GFAP), and Heart Fatty-Acid-Binding Protein (HFABP) to decrease the length of stay in emergency departments, alleviating stress for children and their families.

‍

This multi-center study, which included contributions from ABCDx, University of Geneva, and Vall d'Hebron Hospital, demonstrates the effectiveness of these biomarkers in distinguishing between children with intracranial injuries (ICI) and those without, potentially reducing the need for unnecessary CT scans and shortening hospital observation times.

‍

Exclusive Licensing: ABCDx holds an exclusive license on the patents for these biomarkers, which are owned by the University of Geneva and Vall d'Hebron Hospital. This positions ABCDx at the forefront of innovative diagnostic solutions for pediatric brain injuries.

‍

Quotes:

Anne-Cécile Chiollaz, Lead Author: "Our findings represent a significant advancement in the management of pediatric mTBI. The identified biomarkers can provide a safer, more efficient way to discharge home children suffering from brain injuries." 

Jean-Charles Sanchez, Co-senior Author: "This study exemplifies the power of collaboration in scientific research, bringing together expertise from multiple institutions and ABCDx to improve pediatric care."

‍

About ABCDx: ABCDx is a leading biotech company specializing in diagnostic solutions for brain injuries. With a commitment to innovation and excellence, ABCDx leverages cutting-edge research to develop reliable and effective diagnostic tools.

‍

‍

‍

‍

‍